Study Design and Patients
This open-label, multicenter, phase Ib dose-escalation study aimed to estimate the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of WNT974 + encorafenib + cetuximab in patients with BRAF Eligible patients were 18 years or older; had mCRC with documented 